Latest Breaking News On - Viridia life sciences - Page 1 : comparemela.com

Atai Life Sciences: A Promising Venture In Psychedelic Therapy Trading Below Cash Value

Atai Life Sciences: A Promising Venture In Psychedelic Therapy Trading Below Cash Value
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCity ofUnited kingdomDefense health agencyApeiron investment groupCompany presentationLife sciencesRecognify life sciencesHouse rules committeeAtai life sciencesDefense departmentViridia life sciencesTreatment resistant depressionPresentation novemberBreakthrough therapy designation

Go Higher: Atai Life Sciences Is Moving the Dial on Psychedelic Medicine

To transform the treatment of mental health, clinical-stage biotech atai Life Sciences is peering into the world of psychedelics

New yorkUnited statesCity ofUnited kingdomJohns hopkinsSrinivas raoChristian angermayerEmpath bioEntheogenix biosciencesAtai life sciencesViridia life sciencesApeiron investment groupEarly developmentRecognify life sciencesLife sciencesNigerian efik

Investegate |atai Life Sciences Announcements | atai Life Sciences: atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

Investegate announcements from atai Life Sciences, atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

United kingdomStephen bardinSrinivas raoAllan malievskyLife sciences reports third quarterRecognify life sciencesExchange commissionLife sciencesnv nasdaqViridia life sciencesLife sciencesSecurities exchangeHercules capital incLife sciences virtual rd dayFlorian brandChief executive officerChief scientific

Investegate |atai Life Sciences Announcements | atai Life Sciences: atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

Investegate announcements from atai Life Sciences, atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

Stephen bardinSrinivas raoAllan malievskyExchange commissionLife sciencesnv nasdaqEarly developmentViridia life sciencesLife sciencesLife sciences announces first subject dosedSynthetic formChief scientific officerGlenn shortSenior vice presidentPrivate securities litigation reform actAnnual reportQuarterly reports

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT)

Stephen bardinSrinivas raoAllan malievskyExchange commissionLife sciencesnv nasdaqEarly developmentViridia life sciencesLife sciencesChief scientific officerGlenn shortSenior vice presidentPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reportsExternal affairs